Balazs B Lörincz1, Nathan Jowett1,2, Rainald Knecht1. 1. Department of Otorhinolaryngology, Head and Neck Surgery and Oncology, Head and Neck Cancer Centre of the Hubertus Wald University Cancer Centre Hamburg, University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany. 2. Department of Otolaryngology, Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.
Abstract
BACKGROUND: Transoral robotic surgery (TORS) has become an accepted first-line treatment for T1 and T2 head and neck squamous cell carcinoma (HNSCC). The growing popularity of this procedure is the result of mounting skepticism as to the survival and quality of life (QOL) benefits of primary chemoradiation over definitive surgery, the rising incidence of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) in progressively younger patients, and the advantages of TORS over transoral laser microsurgery (TOLM) and open surgery. METHODS: The authors use their experience and data gained from the TORS-based management of >100 patients to establish a systematic approach to the use of TORS in HNSCC. RESULTS: This approach is constructed on a framework which goal is to select the primary treatment option that is most likely to reduce morbidity while preserving function and maintaining oncologic safety. CONCLUSION: A consensus regarding the indications of TORS and its role in the multidisciplinary management of HNSCC is to be established.
BACKGROUND: Transoral robotic surgery (TORS) has become an accepted first-line treatment for T1 and T2 head and neck squamous cell carcinoma (HNSCC). The growing popularity of this procedure is the result of mounting skepticism as to the survival and quality of life (QOL) benefits of primary chemoradiation over definitive surgery, the rising incidence of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) in progressively younger patients, and the advantages of TORS over transoral laser microsurgery (TOLM) and open surgery. METHODS: The authors use their experience and data gained from the TORS-based management of >100 patients to establish a systematic approach to the use of TORS in HNSCC. RESULTS: This approach is constructed on a framework which goal is to select the primary treatment option that is most likely to reduce morbidity while preserving function and maintaining oncologic safety. CONCLUSION: A consensus regarding the indications of TORS and its role in the multidisciplinary management of HNSCC is to be established.
Authors: Axel Sahovaler; David E Eibling; Ida Bruni; Uma Duvvuri; S Danielle MacNeil; Anthony C Nichols; John Yoo; Kevin Fung; Kathryn Roth Journal: J Robot Surg Date: 2019-01-23
Authors: Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Jennifer R Cracchiolo; Shrujal S Baxi; Luc G Morris; Ian Ganly; Snehal G Patel; Marc A Cohen; Benjamin R Roman Journal: Cancer Date: 2016-03-11 Impact factor: 6.860
Authors: Benjamin R Roman; Shrujal S Baxi; Jennifer R Cracchiolo; Timothy J Blackwell; David G Pfister; Sean McBride; Ian Ganly; Jatin P Shah; Snehal G Patel; Luc G Morris; Marc A Cohen Journal: J Surg Oncol Date: 2017-06-01 Impact factor: 3.454